IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza Signs Manufacturing Deal with U.S. Biopharma Firm

11:52 PM MST | November 24, 2009 | Deepti Ramesh

Lonza says it has entered into an agreement with biopharmaceutical company Micromet (Bethesda, MD) for the process development and manufacture of Micromet’s blinatumomab, a BiTE antibody for the treatment of various hematologic cancers. Micromet develops novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Lonza will manufacture blinatumomab for clinical trials, under the terms of the deal. In addition, Lonza will develop the commercial scale process and will supply blinatumomab for the market if requested by...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa